NEWS

May 15, 2018 | TruPharma Launches Additional Strength of Cyclobenzaprine HCl Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Cyclobenzaprine Hydrochloride 7.5 mg Tablets on the TruPharma label. This limited competition item is being supplied to TruPharma pursuant to a master agreement with Rubicon Research Private Limited. TruPharma previously launched the 5 mg, 10, mg tablet products.

May 1, 2018 | TruPharma Launches Baclofen Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Baclofen 5 mg, 10 mg, and 20 mg Tablets on the TruPharma label. The FDA-approved products are being supplied to TruPharma pursuant to a master agreement with Rubicon Research Private Limited. Significantly, Rubicon holds the only FDA approval for a 5 mg Baclofen Tablet product, and TruPharma will be the single source supplier to the market for this item.

March 16, 2018 | TruPharma In-Licenses Five ANDA Products

TAMPA, Florida – TruPharma, LLC (TruPharma) announced that pursuant to a master agreement with a collaboration partner, it has in-licensed five ANDA products that will be sold on the TruPharma label. The products and partner are confidential pending launch. TruPharma expects the products to launch in 2018.

November 8, 2017 | TruPharma Commences Sales and Distribution of Versacloz™ Brand Clozapine Oral Suspension on Behalf of Tasman Pharma, Inc.

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement with Tasman Pharma, Inc. (Tasman), it has commenced sales and distribution of Versacloz™ Brand (Clozapine, USP) Oral Suspension, 50mg/mL. Tasman recently acquired the approved NDA for Versacloz™ from Jazz Pharmaceuticals, and upon closing of that transaction, appointed TruPharma as the exclusive distributor of Versacloz™. With this arrangement, TruPharma has expanded its platform to include distribution of branded pharmaceutical products through purchase and supply agreements with the three major wholesalers, other buying groups, and the federal government.

September 29, 2017 | TruPharma In-Licenses Two Pending ANDA Products

TAMPA, Florida – TruPharma, LLC (TruPharma) announced that pursuant to a master agreement with a collaboration partner, it has in-licensed two pending ANDA products that will be sold on the TruPharma label. The products and partner are confidential pending launch. TruPharma expects the products to launch in 2018.

August 1, 2017 | TruPharma Launches Cyclobenzaprine HCl Tablets and Clonidine HCl Tablets on a TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Cyclobenzaprine Hydrochloride Tablets 5 mg & 10 mg, and Clonidine Hydrochloride Tablets 0.1 mg, 0.2 mg & 0.3 mg on the TruPharma label. The FDA-approved products are being supplied to TruPharma pursuant to a master agreement with Frontida BioPharm, Inc., which includes additional products that TruPharma expects to launch in the next eighteen months.

June 6, 2017 | TruPharma Launches Lamotrigine Extended Release Tablets on the TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Lamotrigine Extended Release Tablets, an AB-rated generic version of GlaxoSmithKline’s LAMICTAL® XR. The FDA-approved product is being supplied to TruPharma pursuant to an agreement with Handa Pharmaceuticals, LLC, (a subsidiary of Handa Pharmaceuticals, Inc.). LAMICTAL® is a registered trademark of GlaxoSmithKline.

May 10, 2017 | TruPharma Launches Quetiapine Fumarate ER Tablets on the TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Quetiapine Fumarate ER Tablets on the TruPharma label. FDA has determined that this product is therapeutically equivalent to the reference listed drug (RLD), SEROQUEL® XR Tablets of AstraZeneca Pharmaceuticals LP (AstraZeneca). The product is available in 50 mg (base), 150 mg (base), 200 mg (base), 300 mg (base), and 400 mg (base) strengths. The FDA-approved product is being supplied to TruPharma pursuant to an agreement with Pharmadax USA, Inc. (a subsidiary of Pharmadax, Inc.). SEROQUEL® is a registered trademark of AstraZeneca UK Limited.

April 4, 2017 | TruPharma In-Licenses Several Approved ANDA Products

TAMPA, Florida – TruPharma, LLC (TruPharma) announced that pursuant to a master agreement with a collaboration partner, it has in-licensed five products that will be sold on the TruPharma label. The products and partner are confidential pending launch. TruPharma expects two of the products to launch in 2017, and the others to launch in 2018.

March 7, 2017 | TruPharma Expands and Extends its Agreement to Support Amerigen Pharmaceuticals with its Front End Commercial Operation

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an amendment to its existing agreement with Amerigen Pharmaceuticals, it has agreed to continue sales and marketing of products on the Amerigen label. The agreement now covers three products currently on the market, and five other product applications on file with the FDA.

March 3, 2017 | TruPharma Launches Cyproheptadine Hydrochloride Tablets on the TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it launched Cyproheptadine Hydrochloride Tablets on the TruPharma label. The product is available in a 4 mg strength. The FDA-approved product is being supplied to TruPharma pursuant to an agreement with Appco Pharma LLC.

February 22, 2017 | TruPharma Enters Co-Development & Marketing Agreement

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement with a collaboration partner entered February 22, 2017, it has agreed to co-develop two more niche injectable products that will be sold on the TruPharma label. The products and the partner are confidential pending FDA approval of the ANDAs. TruPharma expects the products under development will be submitted to FDA in the first half of 2018.

September 19, 2016 | TruPharma Launches Venlafaxine Tablets on the TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Venlafaxine Tablets on the TruPharma label. The product is available in 25 mg, 37.5 mg, 50 mg, 75 mg, and 100 mg strengths. The FDA-approved product is being supplied to TruPharma pursuant to an agreement with Yaopharma Co., Ltd.

September 1, 2016 | TruPharma Announces the Appointment of Vice President of National Accounts

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that Nick Giffen has joined the company and will serve as TruPharma’s Vice President of National Accounts. Mr. Giffen has over ten years of sales and account management experience in the healthcare industry, having served in various positions with KV Pharmaceutical, Ferris Manufacturing Corporation, Acella Pharmaceutical, and most recently at BioComp Pharmaceutical.

August 15, 2016 | TruPharma Launches Glyburide Tablets on the TruPharma Label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Glyburide Tablets USP on the TruPharma label. The product is available in 1.25 mg, 2.5 mg and 5 mg strengths. The FDA-approved product is being supplied to TruPharma pursuant to an agreement with Pharmadax USA, Inc. (a subsidiary of Pharmadax, Inc.).

July 6, 2016 | TruPharma Announces the Appointment of Corporate Controller

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that Henry “Hank” Daude has joined the company and will serve as TruPharma’s first Corporate Controller. Mr. Daude has over thirty years of finance and accounting experience in the pharmaceutical industry, having served in various positions with Ethex Corporation/KV Pharmaceutical, and most recently at Virtus Pharmaceuticals, LLC.

May 19, 2016 | TruPharma Adds Two Co-Development Projects to Existing Master Collaboration Agreement

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an existing agreement entered in 2015 with a collaboration partner, it has added two products that will be developed and are expected to be submitted to the FDA for review in 2017. The products and the partner are confidential pending FDA approval of the ANDAs.

April 2016 | TruPharma In-Licenses Two Approved ANDA Products

TAMPA, Florida – TruPharma, LLC (TruPharma) announced that pursuant to two separate agreements with different supply partners, it has licensed two approved generic products, and plans to launch the products in 2016.

December 18, 2015 | TruPharma Enters Multiple-Product Development and Marketing Agreement with Pharmadax USA, Inc.

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to a December 18, 2015 agreement with Pharmadax USA, Inc. (a subsidiary of Pharmadax, Inc.), it has agreed to co-develop and market a portfolio of niche products that will be sold on the TruPharma label. The current product portfolio consists of multiple products, some of which are pending with FDA and others are to be developed in the next eighteen months. The agreement contemplates that additional products will be added for future development. TruPharma expects the first of the pending ANDA products to receive FDA approval and to be launched in 2016.

November 18, 2015 | TruPharma Enters Co-Development & Marketing Agreement

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement with a collaboration partner entered November 18, 2015, it has agreed to co-develop a portfolio of niche products that will be sold on the TruPharma label. The products and the partner are confidential pending FDA approval of the ANDAs. TruPharma expects the first two products that are subject to the agreement to be submitted to FDA in 2016.

September 9, 2015 | TruPharma Enters Agreement to Support a Fourth Company with Its Sales & Marketing Needs for the US Market

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement entered as of September 9, 2015, it has agreed to support a fourth company with the launch of its commercial operation for the US market. TruPharma’s partner, which shall remain confidential pending the launch of its first product, has an extensive pipeline of pending ANDAs, and expects the first products on this new label to launch in mid-2016.

May 20, 2015 | TruPharma In-Licenses Pending ANDA Products

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to two separate agreements with its collaboration partners, it has in-licensed products that will be sold on the TruPharma label. The products and partners are confidential pending FDA approval of the pending ANDAs. TruPharma expects the products to be approved and launched in 2016.

February 2, 2015 | TruPharma Supports Orchid Pharma, Inc. with Its Sales & Marketing Needs for the US Market

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement entered in January 2015, Orchid Pharma, Inc. has engaged TruPharma to manage the day-to-day sales & marketing of its existing portfolio of approximately fifteen FDA-approved ANDA products, as well as a pipeline of pending ANDA products. TruPharma will support its existing US operation with the sales, marketing and distribution of these products on the Orchid label.

July 2014 | TruPharma Announces the Appointment of Chief Sales & Marketing Officer

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that Steven Randazzo has joined the company as a partner and will serve as TruPharma’s Chief Sales & Marketing Officer. Mr. Randazzo has over twenty years of sales and marketing experience, having served in various positions with Anchen Pharmaceuticals, KV/Ethex Pharmaceuticals, and most recently, Lupin Pharmaceuticals.

March 15, 2014 | TruPharma Supports Amerigen Pharmaceuticals with the Launch of its Carbidopa 25mg Tablets (a generic equivalent of Valeant’s Lodosyn®) on the Amerigen label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement entered in November 2013, it has worked with Amerigen Pharmaceuticals to establish that company’s commercial platform, and to launch its recently-approved Carbidopa 25mg Tablets (a generic equivalent of Valeant’s Lodosyn®) on an Amerigen label. TruPharma continues to work with Amerigen to manage the sales, marketing and distribution of the product.

January 15, 2014 | TruPharma Supports Strides Pharma., Inc. with the Launch of products on the Strides label

TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement entered in September 2013, it assisted Strides Pharma., Inc. with the establishment of a commercial platform for the US market. This infrastructure allowed Strides to launch its first four products in the US market on the Strides label. TruPharma continues to support Strides with the sales, marketing and distribution of these existing products, and will launch additional products for Strides over the next several years.

 

TruPharma
prides itself on
being a partner
of choice.Ideal partners are developers and manufacturers of products who can leverage our experience getting products approved and to market.
TruPharma is a
private company
headquartered in
Tampa, Florida.We serve
customers all
over the United
States and
partner with
developers and
manufacturers all
over the world.